-

Global Genes Launches RARE Entrepreneurial Development & Incubation (REDI) Initiative to Enable Rare Disease Drug Developers with Expertise, Resources

Program to Equip, Connect and Support Rare Disease Innovators and Entrepreneurs with Training, Funding, and Resources to Advance Rare Disease Drug Development

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Global Genes, a leading rare disease patient advocacy organization, today announced the launch of its inaugural RARE Entrepreneurial Development & Incubation (REDI) Initiative. The REDI Initiative serves as a continuum of events, mentorship, training and visibility designed to support budding leaders in the rare disease community as they, often out of necessity, take on drug discovery and development in rare diseases.

“There are more than 10,000 rare diseases worldwide, more than 95% of which have no approved treatment,” said Craig Martin, CEO of Global Genes. “For many patients, caregivers and advocates, the burden to generate interest, funding and progress toward treatments fall squarely and solely on their shoulders – which is driving an increasing number of caregivers and advocates to become drug developers.”

To prepare emerging rare disease entrepreneurs to navigate through the complexities of various stages of drug development, financing, partnering and commercialization, the REDI initiative will provide participants with training, mentorship, networking opportunities and access to Global Genes event programming and resources geared toward entrepreneurship.

“Through the REDI Initiative, we aim to arm advocates and early-stage entrepreneurs with the tools and guidance to generate and sustain more productive and successful opportunities to develop therapeutic solutions. By combining our expertise and network, we accelerate and expand innovation and build momentum for the entire rare disease ecosystem,” noted Martin.

For more information on participating, email REDI@globalgenes.org.

Global Genes is accepting sponsors and partners for the REDI program. To learn more, see the REDI sponsorship prospectus here.

About Global Genes

Global Genes is a 501(c)(3) non-profit organization dedicated to eliminating the burdens and challenges of rare diseases for patients and families globally. In pursuit of our mission, we connect, empower, and inspire the rare disease community to stand up, stand out, and become more effective on their own behalf ⁠— helping to spur innovation, meet essential needs, build capacity and knowledge, and drive progress within and across rare diseases. We serve the more than 400 million people around the globe and nearly one in 10 Americans affected by rare diseases. If you or someone you love has a rare disease or are searching for a diagnosis, contact Global Genes at 949-248-RARE or visit our Resource Hub.

Contacts

Global Genes:
Laura Vinci
Finn Partners
402-499-8203
laura.vinci@finnpartners.com

Global Genes


Release Versions

Contacts

Global Genes:
Laura Vinci
Finn Partners
402-499-8203
laura.vinci@finnpartners.com

More News From Global Genes

In Partnership with Global Genes, Congenital Hyperinsulinism International Hosts Inaugural Family Meet-Up

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Global Genes, a leading patient advocacy organization, and Congenital Hyperinsulinism International (CHI), a foremost nonprofit dedicated to improving the lives of children and adults living with congenital hyperinsulinism (HI), today announced the inaugural CHI Family Meet-Up. The one-day event aims to provide the opportunity for those in the community and their families to connect, share their stories, and to learn about new findings from the Hyperinsulin...

In Partnership with Global Genes, Youngtimers Hosts Inaugural Leadership Summit

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Global Genes, a leading patient advocacy organization, and Youngtimers, the only US nonprofit organization dedicated to providing education, support, resources for the early onset familial Alzheimer’s disease (EOFAD) community today announced the inaugural Youngtimers Leadership Summit. The four-day event aims to gather key stakeholders to facilitate dialogue around the gaps in the field and how to prioritize the patient perspective, as well as the future o...

Two Leading Rare Disease Organizations Join Forces to Enable and Accelerate Patient-Led Engagement and Advance Research

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Global Genes and RARE-X, leaders in rare disease patient advocacy and capacity building, today announced that their respective boards of directors have signed a definitive agreement to combine the two organizations. This merger will enable the combined organization to provide the next generation of rare disease advocates the tools and resources they need to accelerate their drive for treatments. “This patient-focused, and science-driven partnership will cha...
Back to Newsroom